Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic diseases that associated with increased risk for cardiovascular (CV) diseases and newly CV events. Although CV risk assessment is incorporated in primary and secondary prevention strategies to improve morbidity and mortality that are applied in diabetic patient, it is important to stratify individuals at high CV risk not just prior diabetic complication, but at early stages of development of the CV diseases. The aim of the editorial comment is to discuss possible predictive role of cardiac biomarkers in T2DM. CV biomarkers may contribute to improved prediction of mortality and CV events in T2DM. It has suggested that measurement of serum levels of hs-CRP, galectin-3, natriuretic peptides, fibroblast growth factor-23, α-klotho, and hs-cTnT probably allows the screening of diabetes patients at risk of CV events. Future directions are associated with discovering of novel biomarkers and optimal combinations of recently used markers to provide additional prognostic information beyond what is available with other traditional CV risk factors.